Background: This study evaluated the influence of a triclosan-containing toothpaste in the profile of osteo-immunoinflammatory mediators in peri-implant crevicular fluid (PICF) and in clinical parameters during progression of peri-implant mucositis.
Although implant therapy has been recognized as a promising and predictable strategy to oral rehabilitation, some factors may negatively affect implant survival and promote complications, such as peri-implantitis and peri-implant mucositis, reported as common clinical conditions with relatively high occurrence. [1] [2] [3] Peri-implant mucositis, considered a precursor of peri-implantitis in a similar way that gingivitis is the precursor of periodontitis, 4 is a problem usually encountered in periodontal practices with a prevalence of 48% during an observation period of 9 to 14 years among patients not enrolled in regular supportive periodontal therapy 2 and a prevalence of 20% after 5 years in patients enrolled in regular supportive therapy. 5 Although evidence has indicated that peri-implant mucositis, like gingivitis, is reversible when effectively treated with indicated therapeutic regimens, 6 ,7 the absence of a standard therapeutic protocol results in empirical therapeutic practices in the management of mucositis around implants. 4 Different modalities of treatment have been proposed to treat this disease, and professional plaque control with mechanical therapy (with or without adjunctive use of antimicrobials) [8] [9] [10] or probiotic supplements 11 may represent alternatives to the initial treatment. In general, although the additional benefits promoted by the adjunctive treatments to mechanical therapy in the resolution of peri-implant inflammation is controversial, a recent systematic review did not find improvement in the efficacy of adjunctive approaches in reducing clinical signs of inflammation. 12 However, all the evidence focused on therapeutic alternatives to manage established inflammatory lesions with previous diagnosis of peri-implant mucositis; at present, there are no studies available investigating the use of these strategies during development of peri-implant mucositis. In addition, there is a lack of studies available for primary prevention of peri-implant mucositis. Although patient-administered mechanical plaque control alone with a toothbrush should be considered the current standard of care to prevent periimplant mucositis, 12 the use of active ingredients either by oral rinses or dentifrices could contribute as a preventive measure because the inflammatory response seemed to be even stronger in the peri-implant mucosa than in the gingiva as demonstrated in experimental 13 and human studies. 14 Triclosan (2,4,4, ′ -trichloro-20 ′ hydroxydiphenylether) has been incorporated into toothpaste for many years and has been revealed to be efficient in the control of gingivitis [15] [16] [17] and in reducing the progression of periodontitis. 18, 19 In addition, the efficacy of a triclosan-containing toothpaste in combination with a manual toothbrush was compared with that of a sodium fluoride toothpaste on peri-implant soft tissue conditions in two studies. 20, 21 The regular use of a dentifrice with triclosan was efficient in reducing clinical signs of inflammation in the mucosa adjacent to dental implants with previous mucositis 20 and also enhancing dental implant maintenance by reducing dental plaque and peri-implant bleeding. 21 In addition, other data support the antiinflammatory effects of triclosan, including suppression of acute and chronic mediators of inflammation. 22 However, no study is available demonstrating the chemical potential of a triclosan-containing toothpaste as a preventive strategy to inhibit peri-implant mucositis during the development of this lesion around dental implants. Therefore, the present study aimed to evaluate whether a triclosan dentifrice could interfere with clinical parameters and local pattern of osteo-immunoinflammatory mediators in the peri-implant crevicular fluid (PICF) during progression of experimental peri-implant mucositis. The hypothesis was that a triclosan-containing toothpaste could positively modulate the clinical condition around implants and the host osteoimmunoinflammatory response, even during an experimental period of undisturbed peri-implant plaque accumulation.
MATERIALS AND METHODS

Study design
This investigation was designed as double-blind, randomized, crossover study to evaluate the influence of a triclosancontaining toothpaste in the profile of osteo-immunoinflammatory mediators in PICF and in clinical parameters during the progression of experimental peri-implant mucositis. This study was approved by the ethics committee of Paulista University (Protocol 97.117). The ClinicalTrials.gov identifier is NCT03145610.
Population screening
Patient recruitment started in June 2013 and was completed by the end of May 2014. The clinical procedures and evaluations were carried out between August 2013 and June 2014. Data entry and statistical analyses were performed in January 2015. All patients in the study were recruited from patients referred to Paulista University.
Inclusion and exclusion criteria
To be included in the trial, all patients were > 30 years old and presented at least a two-stage unitary screwed implantsupported single-unit crown in the molar or pre-molar region. The implant-abutment connection was external hexagonal, and the implants were in function at least 12 months with a width of keratinized tissue ≥ 2 mm around implants. The peri-implant tissue was healthy (probing depth [PD]) < 4 mm with no bleeding on probing (BOP) and no evidence of radiographic bone loss beyond bone remodeling. 23 Patients were periodontally healthy (no sites with attachment loss and PD > 3 mm) with full-mouth plaque scores (FMPS) 24 and full-mouth bleeding score (FMBS) 25 ≤ 20%.
The exclusion criteria were pregnancy; lactation; smoking; systemic conditions reported during anamnesis that could affect the progression of peri-implant diseases and bone metabolism (e.g., immunologic disorders, diabetes mellitus, unstable or life-threatening conditions); long-term administration of anti-inflammatory, bisphosphonates, and immunosuppressive medications; antibiotic therapies in the previous 6 months; individuals who required bone grafts before or alongside the implant surgery; and history of previous regenerative procedures in the area treated with implant therapy.
All eligible individuals were thoroughly informed of the nature, potential risks, and benefits of their participation in the study, and they each signed an informed consent document.
Experimental groups
Initially, in a pre-experimental phase, all patients were submitted to a prophylaxis procedure, supragingival scaling and polishing of the entire dentition, and instruction in optimal oral hygiene practices to guarantee ability to perform proper plaque control before entering the experimental phase. Following this, patients were re-evaluated to confirm scores at baseline compatible with gingival/mucosal health (FMPS and FMBS < 20%).
Subsequently, using an experimental mucositis protocol, 6, 14, 26 the participants were asked to refrain from oral hygiene practices only in the peri-implant area for a period of 21 days, during which bacterial deposits were allowed to accumulate on all surfaces. Undisturbed plaque accumulation was achieved only in the area near dental implants by using an individual, partial silicone, soft stent involving the implant and adjacent teeth, covering 2 mm to 3 mm of peri-implant mucosa. During this experimental 3-week period of undisturbed plaque accumulation in the implants, patients were randomly assigned to two groups by a computer-generated list: triclosan (n = 11), triclosan/copolymer/fluoride toothpaste; or placebo (n = 11), fluoride toothpaste, by filling the individual silicone stent with the respective toothpaste according to experimental group and allowing it to come into contact with the implant area for 2 minutes, three times per day. Traditional tooth brushing was performed in the non-stent areas.
After 3 weeks, professional prophylaxis was performed and a washout period of 30 days was established. All patients restarted their optimal mechanical plaque control practices to reach pre-experimental levels of oral cleanliness and gingival/mucosal health. Then, a second experimental 3-week period of undisturbed plaque accumulation in the implants was established and the experimental groups were exchanged.
After that, a new professional prophylaxis was performed. Patients were blinded to the therapies.
All evaluations (clinical and immuno-enzymatic assays) were performed at baseline and 3, 7, 14, and 21 days of each period of experimental mucositis induction. Levels of osteoimmunoinflammatory mediators were considered the primary outcome variable of this study. The number of patients included in the present study was based on previous crossover investigations that found differences in the crevicular fluid levels of osteo-immunoinflammatory markers in different clinical status. 27,28
Clinical examination
The same examiner (BMN), who was blinded to the groups, performed all measurements of clinical assessment. To perform intra-examiner calibration, 15 non-study individuals with dental implants were selected. The examiner measured PD of all patients twice within 24 hours. The examiner was judged to be reproducible after fulfilling the predetermined success criteria (the percentage of agreement within ±1 mm between repeated measurements had to be at least 90%). The intra-class correlation was calculated as 92% reproducibility.
An individual stent was prepared to standardize the location of the periodontal probe * to evaluate the following parameters at four sites of the experimental dental implants at baseline and 3, 7, 14, and 21 days of follow-up: 1) plaque index ([PI] %), scored using a dichotomous PI along the mucosal margin around implants; 2) BOP (%), scored using dichotomous index of bleeding during probing around implants; 3) position of the peri-implant margin ([PPM] mm), which was the distance from the stent to the peri-implant margin; 4) relative clinical attachment level ([RCAL] mm), which was the distance from the stent to the bottom of the peri-implant pocket; and 5) periimplant PD (mm), calculated by deducting PPM from RCAL. The FMPS 24 and FMBS 25 were calculated before the beginning of each period of experimental mucositis induction.
Osteo-immunoinflammatory profile assessment
Peri-implant crevicular fluid was collected from dental implant sites by the same examiner (BMN). The area was isolated and dried, and fluid was collected at two sites of the experimental dental implants (vestibular and lingual) by placing filter paper strips † into the sulcus until the clinician perceived a slight resistance, and then leaving in place for 15 seconds. The fluid volume was measured with a calibrated, electronic gingival fluid measuring device. ‡ Unknown fluid volumes on filter paper strips are determined from calibration graphs constructed by using accurately measured quantities of fluid, according to the manufacturer's recommendations. Then, the strips were placed into sterile tubes containing 400 L of phosphate-buffered saline with 0.05% nonionic detergent. * Peri-implant crevicular fluid samples were immediately stored at −20 • C.
Levels of interferon (INF)-; interleukin (IL)-4, IL-17, IL-1 , IL-10, IL-6, IL-23; tumor necrosis factor (TNF)-; † osteoprotegerin (OPG); osteocalcin (OC); osteopontin (OPN); ‡ matrix metalloproteinase (MMP)-2, MMP-9; § transforming growth factor (TGF)-; ¶ and crosslinked telopeptide of type I collagen (ICTP) # in the peri-implant fluid were determined using commercially available kits. Assays were carried out with 25 L of sample according to the manufacturer's recommendations using the MAGpix TM instrument. ‖ The samples were individually analyzed, and concentrations were estimated from the standard curve using a five-parameter polynomial equation using software. * * The mean concentration of each mediator was calculated using the individual as a statistical unit and expressed as pg/mL.
Data analysis
All analyses were performed using appropriate software. † † Data were first examined for normality using the Kolmogorov-Smirnov test; the data that achieved normality were analyzed using parametric methods. Clinical parameters and the local levels of osteo-immunoinflammatory mediators were averaged into placebo and triclosan groups. FMPS and FMBS measured before the beginning of each period of experimental mucositis induction in both groups were compared using the Wilcoxon test. For the other clinical parameters (PI, BOP, PPM, RCAL, and PD), analysis of variance (ANOVA) two-way Tukey test was used to detect differences between groups and periods. Concentrations of osteo-immunoinflammatory markers between groups and among follow-ups were compared using the Wilcoxon and Friedman tests, respectively. An experimental level of significance was determined at 5% for all statistical analyses. * Tween ® 20 Sigma, Saint Louis, Missouri, USA. † Human Th17 HTH17MAG-14K, Millipore Corporation, Billerica, MA. ‡ Human Bone HBNMAG-51K, Millipore Corporation. § Human MMP Panel 2 HMMP2MAG-55K, Millipore Corporation. ¶ Multi-species TGF TGFBMAG-64K, Millipore Corporation.
# Uscn Life Science Inc., Wuhan, Hubei, China.
‖ MiraiBio, Alameda, CA. * * Xponent ® , Millipore, Corporation. † † SAS, 9.1, Cary, NC.
RESULTS
Initially, 180 individuals were assessed. After examination, 158 patients did not meet inclusion criteria, leaving twentytwo patients for inclusion in the study. No dropout occurred (Fig. 1) . The study population was characterized as 36.37% male (mean age: 48.45 ± 13.64 years).
Clinical results
No significant differences for FMPS (10.4 3 ± 6.22 and 9.36 ± 5.9, for the first and second periods of mucositis induction, respectively; P > 0.05) and FMBS (3.46 ± 2.27 and 2.1 8± 1.11, for the first and second periods of mucositis induction, respectively; P > 0.05) before the beginning of each phase of experimental mucositis were detected. A significant increase in PI at experimental implant sites was detected in both triclosan and placebo groups from the third day (P < 0.05), augmenting steadily until the 21st day (P < 0.05; Table 1 ). Conversely, only triclosan treatment was efficient in preventing a significant increase in bleeding index (BI) throughout the period of undisturbed plaque (P > 0.05; Table 1 ), whereas a significant increase in the percentage of bleeding was observed from the 14th day in the placebo group (P < 0.05; Table 1 ). The means of the PD, RCAL, and PPM at the experimental sites were not statistically different between groups at any time points and no intragroup differences were detected throughout the period of mucositis induction for both treatments (P > 0.05; Table 1 ). Tables 2 through 4 show the peri-implant fluid levels of all biomarkers evaluated for both groups.
Osteo-immunoinflammatory levels
Concerning anti-inflammatory mediators, IL-10 levels decreased only in placebo-treated implant sites, presenting significantly lower concentrations at 21 days when compared with baseline (P = 0.0051; Table 2 ). Additionally, intergroup analysis showed that reduced levels of IL-10 were detected in the placebo group at the 21st day when compared with triclosan-treated implant sites (P = 0.0036; Table 2 ). Regarding pro-inflammatory mediators, IL-1 levels increased during the progression of mucositis only in the placebo group, with significantly higher amounts at 21 days when compared with baseline (P = 0.041; Table 2 ), although no intergroup differences have been detected (P > 0.05; Table 2 .) No intraor intergroup differences were observed for the other inflammatory mediators (IL-4, IL-17, IL-6, IL-23, INF-, TNF-) (P > 0.05; Table 2 ) and the matrix metalloproteinase family (MMP-2, MMP-9) (P > 0.05; Table 3 ).
Concerning the bone-related factors, OPG concentration was significantly augmented from the 14th (P = 0.02) until the 21st day (P = 0.034) when compared with baseline and 7 days only in triclosan-treated sites (Table 4) . No intra-or intergroup differences were observed for OC, OPN, TGF-, and ICTP (P > 0.05; Table 4 ).
DISCUSSION
Although some investigations have focused study on therapeutic alternatives to manage established peri-implant mucositis, 7-10 presently there is a lack of data available concerning the role of preventive strategies to control the development and progression of mucositis around implants, and no study until now demonstrated the chemical potential of a triclosan-containing toothpaste as a protective approach to inhibit peri-implant tissue inflammation around dental implants. Thus, the objective of this study was to evaluate whether a triclosan dentifrice could positively interfere with clinical parameters and local osteo-immunoinflammatory mediators in the PICF during the progression of experimental peri-implant mucositis. In general, only triclosan-treated implant sites prevented increase in BOP throughout the period of undisturbed plaque, whereas intensified bleeding was detected from the 14th day only in placebo-treated sites. The use of toothpaste containing triclosan/copolymer, in addition to fluoride, was also promising to modulate the levels of important pro-and anti-inflammatory mediators and bone-related markers around implants. Triclosan, an active bis-phenolic and non-cationic agent provided efficient results in the treatment of gingivitis, 17, 29, 30 and controlling the progression of periodontitis around natural teeth. 18, 19, 30, 31 Considering the impact of triclosan on periimplant soft tissue conditions, studies have demonstrated that the use of a dentifrice with triclosan was efficient to reduce the clinical signs of inflammation in the mucosa adjacent to dental implants with previous mucositis, favoring dental implant maintenance by reducing dental plaque and marginal bleeding. 20, 21 While these previous studies examined the role of a triclosan/copolymer dentifrice in controlling pre-existing peri-implant diseases, the present double-blind, randomized, crossover investigation focused on examining the effects of triclosan dentifrice on the prevention of peri-implant mucositis, even in the presence of undisturbed biofilm. Interestingly, clinical observations from the current study revealed that peri-implant sites assigned to daily triclosan/copolymer dentifrice use did not present an increase in BOP throughout the period of plaque accumulation (P > 0.05; Table 1 ), whereas a more pronounced inflammatory response was observed from the 14th day of experimental mucositis in placebo-treated sites (P < 0.05; Table 1 ). In fact, the effectiveness of triclosan/copolymer-containing dentifrice in the reduction of both gingival and peri-implant bleeding 20, 21, 32 when compared with a conventional fluoride dentifrice is supported by previous data. According to the Ramberg et al. 20 study comparing the effect of toothpaste with triclosan versus sodium fluoride toothpaste in patients with mucositis around implants, following a period of 6 months, BOP was decreased in the triclosan-managed sites from 53.8% to 29.1%, whereas in the control group values increased from 52.3% to 58.8%. Previous clinical studies have described a cause-and-effect relationship between experimental plaque accumulation and the development of peri-implant mucositis, 6 ,33 and although 6-month well-conducted clinical trials have demonstrated the efficacy of a dentifrice with triclosan to reduce clinical signs of inflammation in the mucosa adjacent to dental implants with previous mucositis, 20,21 the impact of a chemical protocol in the prevention of soft tissue lesions around implants with biofilm accumulation was not investigated. Although only sites receiving triclosan demonstrated inhibition in peri-implant bleeding throughout the current experiment, both placebo and triclosan-treated sites demonstrated an increase in PI from the 3rd day of absence of toothbrushing, and a higher percentage of plaque was detected until the 21st day of the experiment. In contrast, previous findings, based on studies in which mechanical plaque control was performed, indicated significantly less dental plaque on dental implants treated with triclosan/copolymer when compared with implants treated with fluoride toothpaste at the 3-and 6-month evaluations. 21 According to the authors, the use of triclosan dentifrice during 6 months achieved a 13% reduction in dental plaque scores around the dental implants, and this outcome corresponded to the clinical observations for BI leading to a reduction of 22% in peri-implant marginal bleeding. 21 Conversely, in the current study, triclosan therapy avoided inflammatory clinical signs in terms of BOP even in the presence of biofilm. In agreement, other studies indicated that reduction in inflammatory scores following the use of a triclosan-containing dentifrice was more pronounced compared with the reduction in plaque score, 20, 34 confirming the anti-inflammatory potential of triclosan. 30 Thus, it could be hypothesized that this promising clinical outcome would be likely attributed to the encouraging anti-inflammatory effects of triclosan in controlling the immunoinflammatory response.
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IL-10 is recognized to be an anti-inflammatory mediator produced by T-helper 2 (TH2) cells, macrophages, and B cells, which inhibit production of pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-. 35 Interestingly, current study outcomes demonstrated that levels of the important antiinflammatory biomarker, IL-10, were higher at the 21st day in sites treated with triclosan when compared with placebo. Indeed, IL-10 concentrations were significantly reduced only in placebo-treated implant sites throughout the study when compared with baseline values (P < 0.05; Table 2 ), supporting the encouraging role of triclosan in modulating this antiinflammatory mediator. Casado et al., 36 studying the inflammatory process around implants, showed that high levels of IL-10 were compatible with healthy peri-implant conditions, whereas augmented concentrations of IL-10 were detected in mucositis patients when compared with peri-implantitis patients, suggesting the importance of IL-10 as a biochemical marker for determining the diseased status of peri-implant tissues. Other results have not found significant difference in IL-10 levels between patients with or without peri-implantitis. 37 However, the present study was the first to assess the impact of triclosan on levels of anti-inflammatory biomarkers in periimplant crevicular fluid, making it difficult to compare the current outcomes with previous data.
When analyzing pro-inflammatory mediators, results from this investigation demonstrated that levels of IL-1 were augmented during the development of mucositis only in placebotreated sites, showing higher concentrations at the 21st day when compared with baseline (P < 0.05; Table 2 ). IL-1 is a pro-inflammatory cytokine with a central role in periodontal tissue destruction and in progression of peri-implant disease. 38, 39 Higher peri-implant levels of IL-1 have also been identified in advanced mucositis lesions compared with healthy control implants. 38, 40 Moreover, in agreement with Petkovic et al., 41 IL-1 is increased in peri-implant fluid according to the progression of inflammation, since the periimplant inflamed tissue had higher concentrations of IL-1 than peri-implant tissue with non-inflamed or slightly inflamed tissue. In fact, the promising effects of triclosan resulting in the inhibition of pro-inflammatory mediator production, such as INF-, IL-6, prostaglandin E2, and IL-1 , have been supported by earlier findings, 22, 29, 30, 42 although no information is available concerning the role of triclosan in the pro-inflammatory biomarkers in PICF around dental implants, as observed in the current trial.
The inflammatory condition around implant tissues may coexist with bone loss of the implant, leading to increased probing depth in patients with peri-implatitis. 23 Although peri-implant mucositis is a reversible inflammatory reaction of mucosa without loss of supporting bone, when analyzing the bone-related factors in this study, OPG concentrations were significantly increased from the 14th until the 21st day when compared with baseline and 7 days only in triclosantreated implants (P < 0.05; Table 4 ). Interestingly, in the Barros et al. 22 study, it was reported that bone morphogenetic protein (BMP)-2 and BMP-6 synthesis were up-regulated by triclosan. It is important to note that molecules such as OPG are also known as osteoclastogenesis inhibitory factors, being associated with periodontal health 43 and supporting an additional protective effect for using triclosan during the development of peri-implant mucositis, according to the findings of the present study.
It is important to highlight that most of the clinical studies with triclosan showing its effect against gingivitis were conducted for 6 months or longer, [44] [45] [46] although it has already been reported that triclosan's antigingivitis influence can be detected in 6 weeks. 29 In the current study, an experimental period of only 3 weeks was established based on a 21-day experimental mucositis model, considering that this interval is appropriate for experimentally inducing mucositis without promoting irreversible tissue injuries. 6, 14 However, it would be interesting to examine whether longer treatment duration using triclosan could achieve more robust clinical improvements and further benefits in terms of local osteoimmunoinflammatory host response, modulating additional biomarkers whose concentrations were not significantly modified by using triclosan during 3 weeks.
Most of studies investigating the role of triclosan on periodontal and peri-implant tissues were based on pre-existing lesions, and scarce information is available concerning the preventive impact of this agent. [18] [19] [20] [21] Importantly, a recent clinical trial evaluating the preventive effect of triclosan during experimental gingivitis revealed no differences in mean plaque and gingival index values between triclosan or control dentifrice groups, 47 consistent with a previous study. 48 In addition, Pancer et al. 47 study failed to demonstrate that host response biomarkers changes with triclosan treatment. Conversely, although in our study no differences in BI were observed between groups, triclosan was able to inhibit inflammatory process around implants during the 21-day experimental mucositis induction period, and it also was efficient in modulating some important osteo-immunoinflamamtory mediators. The underestimated preventive actions of triclosan in previous studies using experimental gingivitis models 47, 48 may be related to the higher susceptibility to aggravated inflammatory response in the peri-implant mucosa than in the tissues around teeth, 13,14 exacerbating both peri-implant clinical response and local host response involving implants exposed to biofilm accumulation when compared with natural teeth sites.
It is important to mention that results observed in this study were valid only for external hexagonal implant-abutment connection. Thus, the present findings need to be considered with caution since evidence has suggested that implant systems using a conical implant-abutment connection may offer improved outcomes with time versus non-conical connection systems in terms of abutment fit, stability, and seal performance, 49 which could have impact in the inflammation of peri-implant tissue during the development of experimental mucositis.
Although the therapy of peri-implant mucositis is considered a prerequisite for avoiding peri-implantitis, 50 prevention of mucositis should be the target of all clinicians, mainly taking into account the Salvi et al. 14 findings revealing that soft tissues around implants develop a stronger inflammatory response to 21 days of experimental plaque accumulation when compared with those of their gingival counterparts. Considering this aspect, and in view of the promising outcomes achieved in the present study in terms of clinical and osteo-immunoinflammatory modulation provided by using triclosan, it is suggested that although patient-administered mechanical plaque control alone with toothbrush should be considered the gold standard of care to prevent peri-implant mucositis, 12 the association with a triclosan-containing dentifrice could offer advantages in preventing the onset of peri-implant mucositis. This additional approach should be considered, especially considering the high prevalence of peri-implant diseases reported in numerous investigations. 1, 5 It is essential to highlight that the use of triclosan, present in several personal care and household products, has generated questions regarding its long-term ecologic impact. 51 In fact, special attention to a possible environment hazard is required. Nevertheless, there is no unanimity concerning a harmful effect of triclosan-containing toothpaste, taking into account the use of this substance in reduced quantity. 52, 53 Thus, additional studies are required to determine if the benefits found in its control of mucositis around dental implants should be ignored because of environmental issues.
CONCLUSIONS
A triclosan-containing toothpaste may benefit the clinical and local osteo-immunoinflammatory host response around implants, even in the absence of normal oral hygiene. While a recent systematic review has suggested that good oral hygiene by patient-administered mechanical plaque control and a rigorous maintenance program are essential to prevent the establishment and/or recurrence of peri-implant diseases, 54 daily use of a triclosan/copolymer toothpaste can represent an important adjunctive at-home approach to provide additional advantages to inhibit peri-implant mucositis. In addition, although previous longitudinal well-conducted clinical trials have concluded that the regular use of a dentifrice with triclosan is effective to treat the mucosa adjacent to dental implants with previous mucositis, 20, 21 this is the first study to evaluate the chemical potential of a triclosan-containing toothpaste as a preventive strategy to impede inflammation of peri-implant tissues during the experimental development of mucositis around dental implants. Additional investigations are required to confirm the results provided by this trial.
